DR. GARY DAVID SWERGOLD, MD
Medical Practice at Sheldrake Pl, New Rochelle, NY
License number
New York 160310
Category
Osteopathic Medicine
Type
Internal Medicine
License number
New York 160310
Category
Medical Practice
Type
Clinical Genetics (M.D.)
Address
Address
75 Sheldrake Pl, New Rochelle, NY 10804
Phone
(914) 637-1943
(914) 633-5747 (Fax)
(914) 633-5747 (Fax)
Personal information
See more information about GARY DAVID SWERGOLD at radaris.comName
Address
Phone
450 End Ave, New York, NY 10024
450 End Ave, New York, NY 10024
450 W End Ave, New York, NY 10024
75 Sheldrake Ln, New Rochelle, NY 10804
Professional information
Dr. Gary D Swergold, New Rochelle NY - MD (Doctor of Medicine)
Specialties:
Internal Medicine, Clinical Genetics
Address:
75 Sheldrake Pl, New Rochelle 10804
(914) 637-1943 (Phone), (914) 633-5747 (Fax)
(914) 637-1943 (Phone), (914) 633-5747 (Fax)
Certifications:
Clinical Genetics, 1993, Internal Medicine, 1986
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1983
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1983
Methods For Treating Hypercholesterolemia Using Antibodies To Pcsk9
US Patent:
8357371, Jan 22, 2013
Filed:
Apr 27, 2011
Appl. No.:
13/095234
Inventors:
Mark W. Sleeman - Mahopac NY, US
Joel H. Martin - Putnam Valley NY, US
Tammy T. Huang - Goldens Bridge NY, US
Douglas MacDonald - New York NY, US
Gary Swergold - New Rochelle NY, US
Joel H. Martin - Putnam Valley NY, US
Tammy T. Huang - Goldens Bridge NY, US
Douglas MacDonald - New York NY, US
Gary Swergold - New Rochelle NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 39/395, C07K 16/00, C12P 21/08
US Classification:
4241581, 5303871, 5303879
Abstract:
The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof.
Methods For Treating Hypercholesterolemia Using Antibodies To Pcsk9
US Patent:
2013006, Mar 14, 2013
Filed:
Nov 9, 2012
Appl. No.:
13/672792
Inventors:
Joel H. MARTIN - Putnam Valley NY, US
Tammy T. HUANG - Goldens Bridge NY, US
Douglas MACDONALD - New York NY, US
Gary SWERGOLD - New Rochelle NY, US
Robert C. PORDY - Ardsley NY, US
William J. SASIELA - Bloomingdale NJ, US
Tammy T. HUANG - Goldens Bridge NY, US
Douglas MACDONALD - New York NY, US
Gary SWERGOLD - New Rochelle NY, US
Robert C. PORDY - Ardsley NY, US
William J. SASIELA - Bloomingdale NJ, US
Assignee:
REGENERON PHARMACEUTICALS, INC. - Tarrytown NY
International Classification:
A61K 39/395, A61P 3/00
US Classification:
4241581
Abstract:
The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof.
Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)
US Patent:
2013024, Sep 19, 2013
Filed:
Sep 12, 2012
Appl. No.:
13/611405
Inventors:
Gary Swergold - New Rochelle NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 39/395
US Classification:
4241461
Abstract:
The present invention provides methods for reducing lipoprotein(a) (Lp(a)) in patients. The methods of the present invention comprise selecting a patient who exhibits elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.